# A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects

Source: https://onco.cc/trials/nct07446153/  
OnCo record `nct07446153` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-8364 Tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects is a phase 1/2 interventional study registered as NCT07446153 by Jiangsu HengRui Medicine Co., Ltd., with 282 participants planned, started 2026-03-19 and due to reach its primary completion in 2028-12. Interventions recorded: HRS-8364 Tablet.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07446153
- Phase: 1/2
- Setting: An Open Label, Multicenter Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 282

## Sources

- ClinicalTrials.gov NCT07446153: https://clinicaltrials.gov/study/NCT07446153

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07446153.json